Atenolol and cardiovascular risk: An issue close to the heart

Lancet

Volumn 367, Issue 9511, 2006, Pages 627-629

  Wilkinson, Ian B ^a   McEniery, Carmel M ^a   Cockcroft, John R ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PERINDOPRIL;

AORTA PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; DRUG CHOICE; HUMAN; HYPERTENSION; NOTE; PRIORITY JOURNAL; PULSE PRESSURE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE;

EID: 33344469027     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)68238-X     Document Type: Note

References (16)

1. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 2002 2981 2997
2. JA Staessen, JG Wang, L Thijs Cardiovascular protection and blood pressure reduction: a meta-analysis Lancet 358 2001 1305 1315
3. LH Lindholm, B Carlberg, O Samuelsson Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis Lancet 366 2005 1545 1553
4. B Carlberg, O Samuelsson, LH Lindholm Atenolol in hypertension: is it a wise choice? Lancet 364 2004 1684 1689
5. B Dahlof, RB Devereux, SE Kjeldsen Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 359 2002 995 1003
6. B Dahlof, PS Sever, NR Poulter for the ASCOT investigators Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial Lancet 366 2005 895 906
7. The CAFE investigators for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) investigators Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) Study Circulation 2006 published online Feb 13. DOI:10.1161/CIRCULATIONAHA.105.595496
8. JW Remington, EH Wood Formation of the peripheral pulse contour in man J Appl Physiol 9 1956 433 442
9. ME Safar, J Blacher, B Pannier Central pulse pressure and mortality in end-stage renal disease Hypertension 39 2002 735 738
10. T Morgan, J Lauri, A Anderson Effect of different antihypertensive drug classes on central aortic pressure Am J Hypertens 17 2004 118 123
11. Z Dhakam, CM McEniery, Yasmin, JR Cockcroft, MJ Brown, IB Wilkinson Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity Am J Hypertens 19 2006 214 219
12. JR Cockcroft, MJ Brown Losartan for cardiovascular disease inpatients with and without diabetes in the LIFE study Lancet 359 2002 2202 2204
13. IB Wilkinson, H MacCallum, L Flint, JR Cockcroft, DE Newby, DJ Webb The influence of heart rate on augmentation index and central arterial pressure in humans J Physiol 525 2000 263 270
14. R Kelly, J Daley, A Avolio, M O'Rourke Arterial dilation and reduced wave reflection: benefit of dilevalol in hypertension Hypertension 14 1989 14 21
15. B Williams Pulse wave analysis and hypertension: evangelism versus scepticism J Hypertens 22 2004 447 449
16. IB Wilkinson, JR Cockcroft Cholesterol, endothelial function and arterial stiffness Curr Opin Lipidol 9 1998 237 242